Efemoral Medical, a Los Altos, CA-based developer of advanced interventional bioresorbable therapies, raised $4.9M in Series A1 funding.
The backers were existing investors, as well as an experienced cohort of new investors.
The company intends to use the funds to support increasing enrollment in its ongoing first-in-human trial, EFEMORAL I.
Led by Christopher Haig, CEO, and Lewis B. Schwartz, MD, CMO, Efemoral Medical provides bioresorbable solutions. The Efemoral Vascular Scaffold System (EVSS) with FlexStep Technology offers a new approach to treating peripheral arterial disease (PAD) by addressing the specific anatomical challenges and complex biomechanics of patients with athero-occlusive disease in the leg. Through the use of inter-scaffold spaces, the patented FlexStep Technology combines flexibility with support to accommodate tortuosity and skeletal movement, while the balloon-expandable deployment system easily opens vessels and sustains healthy blood flow. The novel bioresorbable scaffold with long-term Sirolimus elution aims to restore normal vessel diameter at the time of the procedure, deliver therapeutic benefits across all lesion lengths and morphologies, prevent restenosis, and maintain patency while leaving no permanent implant behind.
FinSMEs
13/12/2022